| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Arrest | 45 | 2025 | 376 | 8.240 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 15 | 2025 | 97 | 4.130 |
Why?
|
| Cardiopulmonary Resuscitation | 25 | 2025 | 331 | 3.700 |
Why?
|
| Nitrites | 10 | 2020 | 51 | 3.170 |
Why?
|
| Sodium Nitrite | 5 | 2021 | 6 | 1.610 |
Why?
|
| Emergency Medical Services | 9 | 2025 | 414 | 1.570 |
Why?
|
| Drowning | 4 | 2024 | 45 | 1.350 |
Why?
|
| Hypothermia, Induced | 10 | 2023 | 170 | 1.170 |
Why?
|
| Hospital Mortality | 8 | 2021 | 1088 | 1.150 |
Why?
|
| American Heart Association | 3 | 2024 | 328 | 1.130 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 457 | 1.100 |
Why?
|
| Coma | 6 | 2020 | 57 | 1.070 |
Why?
|
| Neuroprotective Agents | 4 | 2017 | 167 | 1.040 |
Why?
|
| Ischemic Preconditioning | 2 | 2017 | 22 | 0.930 |
Why?
|
| Ventricular Fibrillation | 4 | 2021 | 56 | 0.870 |
Why?
|
| Nitric Oxide | 6 | 2020 | 490 | 0.850 |
Why?
|
| Vasoconstrictor Agents | 5 | 2025 | 146 | 0.840 |
Why?
|
| Drug Overdose | 2 | 2020 | 75 | 0.790 |
Why?
|
| Brain | 8 | 2021 | 3223 | 0.760 |
Why?
|
| Cross Infection | 5 | 2012 | 332 | 0.750 |
Why?
|
| Near Drowning | 3 | 2024 | 26 | 0.740 |
Why?
|
| Surge Capacity | 1 | 2020 | 8 | 0.690 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2020 | 485 | 0.660 |
Why?
|
| Advanced Cardiac Life Support | 2 | 2020 | 18 | 0.640 |
Why?
|
| Pediatricians | 1 | 2020 | 71 | 0.630 |
Why?
|
| Mitochondria | 7 | 2022 | 744 | 0.630 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 79 | 0.630 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 29 | 0.630 |
Why?
|
| Brain Ischemia | 5 | 2018 | 278 | 0.630 |
Why?
|
| Humans | 78 | 2025 | 133390 | 0.620 |
Why?
|
| Coronary Angiography | 2 | 2019 | 483 | 0.600 |
Why?
|
| Intensive Care Units | 6 | 2016 | 537 | 0.590 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 383 | 0.570 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 394 | 0.570 |
Why?
|
| Aftercare | 2 | 2016 | 155 | 0.570 |
Why?
|
| Shock | 2 | 2016 | 98 | 0.560 |
Why?
|
| Neuroprotection | 2 | 2022 | 31 | 0.560 |
Why?
|
| Carbon Dioxide | 1 | 2018 | 289 | 0.550 |
Why?
|
| Myocardium | 3 | 2021 | 1045 | 0.550 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 121 | 0.550 |
Why?
|
| Blood Pressure | 4 | 2021 | 1419 | 0.540 |
Why?
|
| Thigh | 1 | 2017 | 53 | 0.530 |
Why?
|
| Arm | 1 | 2017 | 81 | 0.520 |
Why?
|
| Asphyxia | 4 | 2021 | 14 | 0.520 |
Why?
|
| Heart | 4 | 2023 | 749 | 0.510 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2021 | 1310 | 0.500 |
Why?
|
| Electron Transport Complex I | 2 | 2020 | 33 | 0.490 |
Why?
|
| Catheterization, Central Venous | 3 | 2012 | 135 | 0.480 |
Why?
|
| Sepsis | 3 | 2023 | 517 | 0.470 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 467 | 0.470 |
Why?
|
| Hyperoxia | 4 | 2020 | 130 | 0.470 |
Why?
|
| Hyperlactatemia | 1 | 2014 | 2 | 0.460 |
Why?
|
| Thiamine Deficiency | 1 | 2014 | 4 | 0.460 |
Why?
|
| Thiamine | 1 | 2014 | 10 | 0.460 |
Why?
|
| Random Allocation | 6 | 2020 | 449 | 0.450 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 208 | 0.450 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 44 | 0.440 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2014 | 113 | 0.440 |
Why?
|
| Respiration, Artificial | 6 | 2020 | 500 | 0.440 |
Why?
|
| Critical Illness | 5 | 2023 | 624 | 0.430 |
Why?
|
| Male | 47 | 2025 | 65685 | 0.420 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2017 | 295 | 0.420 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 177 | 0.410 |
Why?
|
| Forecasting | 1 | 2015 | 376 | 0.410 |
Why?
|
| Ischemic Postconditioning | 1 | 2012 | 5 | 0.400 |
Why?
|
| Withholding Treatment | 2 | 2025 | 69 | 0.400 |
Why?
|
| Reactive Oxygen Species | 3 | 2020 | 525 | 0.390 |
Why?
|
| Disease Management | 1 | 2016 | 561 | 0.380 |
Why?
|
| Hypothermia | 2 | 2023 | 61 | 0.370 |
Why?
|
| Reperfusion Injury | 2 | 2015 | 124 | 0.360 |
Why?
|
| Housekeeping, Hospital | 1 | 2011 | 2 | 0.360 |
Why?
|
| Anticoagulants | 1 | 2016 | 599 | 0.360 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 544 | 0.360 |
Why?
|
| Rats | 12 | 2022 | 3883 | 0.350 |
Why?
|
| Administration, Intravenous | 3 | 2025 | 162 | 0.340 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2014 | 202 | 0.340 |
Why?
|
| Shock, Cardiogenic | 2 | 2023 | 211 | 0.340 |
Why?
|
| Ultraviolet Rays | 1 | 2011 | 209 | 0.340 |
Why?
|
| Veins | 1 | 2010 | 108 | 0.320 |
Why?
|
| Infection Control | 1 | 2011 | 151 | 0.320 |
Why?
|
| Epinephrine | 4 | 2025 | 181 | 0.320 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 270 | 0.320 |
Why?
|
| Comorbidity | 3 | 2020 | 1615 | 0.310 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 4778 | 0.310 |
Why?
|
| Animals | 26 | 2022 | 36377 | 0.310 |
Why?
|
| Nervous System | 1 | 2009 | 131 | 0.300 |
Why?
|
| Arteries | 1 | 2010 | 229 | 0.300 |
Why?
|
| Signal Transduction | 6 | 2020 | 4897 | 0.290 |
Why?
|
| Adult | 18 | 2025 | 31786 | 0.290 |
Why?
|
| Female | 38 | 2025 | 71455 | 0.290 |
Why?
|
| Superoxides | 2 | 2020 | 130 | 0.290 |
Why?
|
| United States | 8 | 2025 | 11677 | 0.280 |
Why?
|
| Prospective Studies | 10 | 2025 | 6570 | 0.280 |
Why?
|
| Registries | 6 | 2025 | 1568 | 0.270 |
Why?
|
| Muscle Cells | 1 | 2007 | 27 | 0.270 |
Why?
|
| Life Support Care | 2 | 2025 | 47 | 0.270 |
Why?
|
| Heart Failure | 1 | 2020 | 2420 | 0.260 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 3082 | 0.260 |
Why?
|
| Middle Aged | 24 | 2025 | 29208 | 0.250 |
Why?
|
| Oxygen | 5 | 2020 | 577 | 0.250 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 79 | 0.250 |
Why?
|
| Subclavian Vein | 1 | 2005 | 22 | 0.230 |
Why?
|
| Infusions, Intraosseous | 1 | 2025 | 22 | 0.230 |
Why?
|
| Pennsylvania | 4 | 2020 | 60 | 0.230 |
Why?
|
| Double-Blind Method | 4 | 2021 | 1654 | 0.230 |
Why?
|
| Monitoring, Physiologic | 2 | 2018 | 388 | 0.230 |
Why?
|
| Jugular Veins | 1 | 2005 | 78 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 479 | 0.230 |
Why?
|
| Pyrroles | 1 | 2006 | 187 | 0.230 |
Why?
|
| Femoral Vein | 1 | 2005 | 49 | 0.230 |
Why?
|
| Pneumonia | 2 | 2005 | 342 | 0.220 |
Why?
|
| Hemodynamics | 3 | 2023 | 868 | 0.220 |
Why?
|
| Critical Care | 3 | 2020 | 693 | 0.220 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 514 | 0.220 |
Why?
|
| Catheters, Indwelling | 1 | 2005 | 142 | 0.210 |
Why?
|
| Electroencephalography | 2 | 2018 | 907 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 1733 | 0.210 |
Why?
|
| Drainage | 1 | 2005 | 264 | 0.200 |
Why?
|
| Research Design | 2 | 2018 | 746 | 0.200 |
Why?
|
| Hydrogen Peroxide | 2 | 2022 | 130 | 0.200 |
Why?
|
| Protein Kinase C-delta | 2 | 2014 | 17 | 0.200 |
Why?
|
| Cerebrovascular Circulation | 2 | 2018 | 474 | 0.200 |
Why?
|
| Cross-Over Studies | 3 | 2021 | 328 | 0.200 |
Why?
|
| Resuscitation | 3 | 2020 | 268 | 0.200 |
Why?
|
| Pandemics | 2 | 2020 | 1189 | 0.200 |
Why?
|
| Child | 9 | 2025 | 25733 | 0.200 |
Why?
|
| Cold Temperature | 2 | 2023 | 86 | 0.190 |
Why?
|
| Heart Rate | 2 | 2017 | 600 | 0.190 |
Why?
|
| Catheterization | 1 | 2003 | 235 | 0.190 |
Why?
|
| Survival Analysis | 4 | 2021 | 1596 | 0.190 |
Why?
|
| Recovery of Function | 3 | 2025 | 468 | 0.190 |
Why?
|
| Neurophysiological Monitoring | 2 | 2018 | 38 | 0.190 |
Why?
|
| Brain Injuries | 2 | 2019 | 722 | 0.180 |
Why?
|
| Glycopyrrolate | 1 | 2021 | 10 | 0.180 |
Why?
|
| Survival Rate | 6 | 2020 | 2210 | 0.180 |
Why?
|
| Electric Countershock | 2 | 2019 | 73 | 0.180 |
Why?
|
| Pulse | 1 | 2021 | 29 | 0.180 |
Why?
|
| Bradycardia | 1 | 2021 | 63 | 0.180 |
Why?
|
| Oxidative Stress | 1 | 2006 | 867 | 0.170 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 50 | 0.170 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2020 | 10 | 0.170 |
Why?
|
| Coronavirus | 1 | 2020 | 26 | 0.170 |
Why?
|
| Aged | 14 | 2025 | 21605 | 0.170 |
Why?
|
| Naloxone | 1 | 2020 | 50 | 0.170 |
Why?
|
| Fentanyl | 1 | 2020 | 49 | 0.170 |
Why?
|
| Vasodilation | 2 | 2014 | 179 | 0.170 |
Why?
|
| Myocardial Stunning | 1 | 2020 | 22 | 0.170 |
Why?
|
| Nitrates | 1 | 2020 | 33 | 0.170 |
Why?
|
| Metformin | 1 | 2022 | 162 | 0.170 |
Why?
|
| Brain Edema | 1 | 2020 | 71 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 304 | 0.160 |
Why?
|
| Patient Positioning | 1 | 2020 | 57 | 0.160 |
Why?
|
| Prescription Drugs | 1 | 2020 | 58 | 0.160 |
Why?
|
| Risk Factors | 6 | 2021 | 11085 | 0.160 |
Why?
|
| Respiration Disorders | 1 | 2019 | 32 | 0.160 |
Why?
|
| Bacteremia | 1 | 2003 | 418 | 0.160 |
Why?
|
| Cardiolipins | 1 | 2019 | 18 | 0.160 |
Why?
|
| Partial Pressure | 1 | 2018 | 29 | 0.150 |
Why?
|
| Mitochondria, Heart | 1 | 2019 | 65 | 0.150 |
Why?
|
| Methylprednisolone | 1 | 2019 | 102 | 0.150 |
Why?
|
| Tissue Distribution | 1 | 2019 | 400 | 0.150 |
Why?
|
| Heart Ventricles | 2 | 2020 | 799 | 0.150 |
Why?
|
| Cyclosporine | 1 | 2019 | 148 | 0.150 |
Why?
|
| Metabolomics | 1 | 2022 | 456 | 0.150 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 154 | 0.150 |
Why?
|
| Laboratory Personnel | 1 | 2018 | 3 | 0.150 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2022 | 301 | 0.150 |
Why?
|
| Body Temperature | 4 | 2023 | 130 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 266 | 0.150 |
Why?
|
| Pediatrics | 2 | 2024 | 1217 | 0.150 |
Why?
|
| Time Factors | 7 | 2018 | 6569 | 0.140 |
Why?
|
| Hypoxia, Brain | 1 | 2017 | 35 | 0.140 |
Why?
|
| Goals | 1 | 2018 | 133 | 0.140 |
Why?
|
| Career Mobility | 1 | 2018 | 54 | 0.140 |
Why?
|
| Electrocardiography | 2 | 2021 | 1005 | 0.140 |
Why?
|
| Blood Gas Analysis | 4 | 2020 | 85 | 0.140 |
Why?
|
| Microcirculation | 2 | 2014 | 116 | 0.140 |
Why?
|
| Patient Selection | 2 | 2018 | 732 | 0.140 |
Why?
|
| Neurons | 3 | 2016 | 2036 | 0.130 |
Why?
|
| Cytoprotection | 2 | 2007 | 38 | 0.130 |
Why?
|
| Guanylate Cyclase | 1 | 2016 | 39 | 0.130 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 453 | 0.130 |
Why?
|
| Cell Survival | 2 | 2016 | 888 | 0.130 |
Why?
|
| Seizures | 2 | 2018 | 889 | 0.130 |
Why?
|
| Retrospective Studies | 12 | 2025 | 17378 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 152 | 0.130 |
Why?
|
| Free Radical Scavengers | 1 | 2016 | 57 | 0.130 |
Why?
|
| Hypoxia | 2 | 2020 | 263 | 0.130 |
Why?
|
| Hospitalization | 4 | 2021 | 1892 | 0.130 |
Why?
|
| Brain Diseases | 1 | 2019 | 310 | 0.130 |
Why?
|
| Thermography | 1 | 2016 | 12 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2018 | 224 | 0.130 |
Why?
|
| Ascorbic Acid | 1 | 2016 | 82 | 0.130 |
Why?
|
| Brain Chemistry | 1 | 2016 | 125 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2020 | 569 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 193 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 507 | 0.130 |
Why?
|
| Transitional Care | 1 | 2016 | 19 | 0.130 |
Why?
|
| Body Temperature Regulation | 1 | 2016 | 50 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 201 | 0.120 |
Why?
|
| Respiratory Insufficiency | 1 | 2018 | 239 | 0.120 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 26 | 0.120 |
Why?
|
| Scleroderma, Diffuse | 1 | 2014 | 4 | 0.120 |
Why?
|
| Shock, Hemorrhagic | 1 | 2015 | 58 | 0.110 |
Why?
|
| Brachial Artery | 1 | 2014 | 42 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2018 | 252 | 0.110 |
Why?
|
| Cytokines | 1 | 2021 | 1393 | 0.110 |
Why?
|
| Microvessels | 1 | 2014 | 63 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 93 | 0.110 |
Why?
|
| Caspases | 1 | 2015 | 167 | 0.110 |
Why?
|
| Blood Platelets | 1 | 2017 | 340 | 0.110 |
Why?
|
| Glucose | 2 | 2016 | 923 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2015 | 1336 | 0.110 |
Why?
|
| Swine | 4 | 2019 | 1215 | 0.110 |
Why?
|
| Thermogenesis | 1 | 2014 | 49 | 0.110 |
Why?
|
| Azo Compounds | 1 | 2013 | 11 | 0.110 |
Why?
|
| Anthraquinones | 1 | 2013 | 9 | 0.110 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 80 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2005 | 300 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 930 | 0.110 |
Why?
|
| Phenylenediamines | 1 | 2013 | 30 | 0.110 |
Why?
|
| Cardiac Catheterization | 1 | 2018 | 664 | 0.110 |
Why?
|
| Lung Injury | 1 | 2015 | 123 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2018 | 522 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 4822 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 789 | 0.100 |
Why?
|
| Pilot Projects | 1 | 2017 | 1481 | 0.100 |
Why?
|
| Prevalence | 1 | 2020 | 2651 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2014 | 157 | 0.100 |
Why?
|
| Brain Concussion | 1 | 2015 | 236 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2020 | 1063 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 1190 | 0.100 |
Why?
|
| Axons | 1 | 2015 | 394 | 0.100 |
Why?
|
| Cardiology | 1 | 2018 | 521 | 0.100 |
Why?
|
| S-Nitrosothiols | 1 | 2012 | 4 | 0.100 |
Why?
|
| Methemoglobin | 1 | 2012 | 5 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2022 | 1334 | 0.100 |
Why?
|
| Survivors | 1 | 2015 | 359 | 0.100 |
Why?
|
| Blood Flow Velocity | 1 | 2014 | 466 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 509 | 0.090 |
Why?
|
| bcl-Associated Death Protein | 1 | 2011 | 4 | 0.090 |
Why?
|
| Prognosis | 3 | 2018 | 5074 | 0.090 |
Why?
|
| Cyclic GMP | 1 | 2012 | 105 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 920 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 522 | 0.090 |
Why?
|
| Cytochromes c | 1 | 2011 | 52 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2018 | 5175 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2013 | 286 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 631 | 0.090 |
Why?
|
| Patient Discharge | 3 | 2020 | 517 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2017 | 555 | 0.090 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 983 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2010 | 321 | 0.090 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2012 | 80 | 0.090 |
Why?
|
| Aorta | 1 | 2014 | 560 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 104 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 697 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2014 | 486 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 2014 | 481 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 610 | 0.090 |
Why?
|
| Astrocytes | 1 | 2013 | 272 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 489 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 3025 | 0.080 |
Why?
|
| Logistic Models | 3 | 2021 | 1907 | 0.080 |
Why?
|
| Cognition | 1 | 2015 | 816 | 0.080 |
Why?
|
| Treatment Outcome | 6 | 2018 | 12971 | 0.080 |
Why?
|
| Lung | 1 | 2017 | 1557 | 0.080 |
Why?
|
| Oxygen Consumption | 2 | 2023 | 314 | 0.080 |
Why?
|
| Mice | 6 | 2022 | 18910 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2018 | 3696 | 0.070 |
Why?
|
| Young Adult | 3 | 2021 | 9852 | 0.070 |
Why?
|
| Incidence | 3 | 2005 | 3396 | 0.070 |
Why?
|
| Anions | 1 | 2007 | 18 | 0.070 |
Why?
|
| Lactic Acid | 2 | 2021 | 166 | 0.070 |
Why?
|
| Rewarming | 2 | 2017 | 12 | 0.070 |
Why?
|
| Arterial Pressure | 2 | 2021 | 119 | 0.070 |
Why?
|
| Adolescent | 5 | 2025 | 20505 | 0.070 |
Why?
|
| International Cooperation | 2 | 2017 | 167 | 0.060 |
Why?
|
| Endocrine System | 1 | 2006 | 22 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2020 | 814 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2025 | 14788 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 2161 | 0.060 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 104 | 0.060 |
Why?
|
| Cause of Death | 2 | 2018 | 504 | 0.060 |
Why?
|
| Models, Animal | 1 | 2007 | 483 | 0.060 |
Why?
|
| Organ Dysfunction Scores | 2 | 2015 | 51 | 0.060 |
Why?
|
| Glottis | 1 | 2005 | 31 | 0.060 |
Why?
|
| Administration, Inhalation | 2 | 2015 | 187 | 0.060 |
Why?
|
| Canada | 1 | 2025 | 343 | 0.060 |
Why?
|
| Stroke | 1 | 2012 | 1068 | 0.060 |
Why?
|
| Kidney | 2 | 2022 | 1416 | 0.050 |
Why?
|
| Shivering | 1 | 2023 | 2 | 0.050 |
Why?
|
| Equipment Safety | 1 | 2003 | 37 | 0.050 |
Why?
|
| Infant | 3 | 2025 | 13158 | 0.050 |
Why?
|
| Consensus | 2 | 2017 | 737 | 0.050 |
Why?
|
| Equipment Contamination | 1 | 2003 | 40 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2005 | 168 | 0.050 |
Why?
|
| Staurosporine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Probability | 1 | 2003 | 335 | 0.050 |
Why?
|
| Rodentia | 1 | 2022 | 47 | 0.050 |
Why?
|
| Glutamates | 1 | 2022 | 70 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2087 | 0.050 |
Why?
|
| Substrate Specificity | 2 | 2014 | 311 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2005 | 406 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2015 | 644 | 0.050 |
Why?
|
| Troponin | 1 | 2022 | 78 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 125 | 0.050 |
Why?
|
| Austria | 1 | 2021 | 20 | 0.050 |
Why?
|
| Intubation, Intratracheal | 1 | 2005 | 291 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 604 | 0.050 |
Why?
|
| Heart Function Tests | 1 | 2021 | 58 | 0.040 |
Why?
|
| Potassium Chloride | 1 | 2020 | 55 | 0.040 |
Why?
|
| Adhesives | 1 | 2020 | 10 | 0.040 |
Why?
|
| Death | 1 | 2021 | 80 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 429 | 0.040 |
Why?
|
| Airway Extubation | 1 | 2021 | 70 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2294 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 1210 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 1999 | 41 | 0.040 |
Why?
|
| Temperature | 1 | 2020 | 330 | 0.040 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 1999 | 38 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1999 | 73 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2019 | 85 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 757 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 197 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2019 | 171 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2018 | 32 | 0.040 |
Why?
|
| Classification | 1 | 2018 | 19 | 0.040 |
Why?
|
| Washington | 1 | 2018 | 35 | 0.040 |
Why?
|
| Work Engagement | 1 | 2018 | 4 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 1999 | 173 | 0.040 |
Why?
|
| Time Management | 1 | 2018 | 12 | 0.040 |
Why?
|
| Selection Bias | 1 | 2018 | 22 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 1999 | 228 | 0.040 |
Why?
|
| Publication Bias | 1 | 2018 | 17 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 480 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 465 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2018 | 65 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2018 | 50 | 0.030 |
Why?
|
| Catheters | 1 | 2017 | 84 | 0.030 |
Why?
|
| Hospitals | 1 | 2020 | 429 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 7159 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 365 | 0.030 |
Why?
|
| Self Care | 1 | 2018 | 223 | 0.030 |
Why?
|
| Mentors | 1 | 2018 | 160 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 134 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2016 | 105 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2020 | 505 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 245 | 0.030 |
Why?
|
| Burnout, Professional | 1 | 2018 | 130 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 997 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 3733 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2018 | 392 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 296 | 0.030 |
Why?
|
| Maze Learning | 1 | 2015 | 126 | 0.030 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 198 | 0.030 |
Why?
|
| Lung Compliance | 1 | 2015 | 20 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2015 | 33 | 0.030 |
Why?
|
| Microdialysis | 1 | 2015 | 57 | 0.030 |
Why?
|
| Mouth Floor | 1 | 2014 | 1 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 433 | 0.030 |
Why?
|
| Length of Stay | 2 | 2014 | 1381 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2014 | 51 | 0.030 |
Why?
|
| Manometry | 1 | 2014 | 73 | 0.030 |
Why?
|
| Fingers | 1 | 2014 | 68 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2014 | 79 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1464 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 332 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2022 | 3981 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2014 | 21 | 0.030 |
Why?
|
| Basal Metabolism | 1 | 2014 | 96 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2014 | 151 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2014 | 66 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 395 | 0.030 |
Why?
|
| Electrodes | 1 | 2013 | 97 | 0.030 |
Why?
|
| Models, Biological | 2 | 2011 | 1532 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2014 | 122 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1124 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2014 | 144 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1241 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 469 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 332 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2013 | 318 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 292 | 0.020 |
Why?
|
| Disinfectants | 1 | 2012 | 28 | 0.020 |
Why?
|
| Chlorhexidine | 1 | 2012 | 47 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1760 | 0.020 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2011 | 17 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3642 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2011 | 29 | 0.020 |
Why?
|
| Checklist | 1 | 2012 | 95 | 0.020 |
Why?
|
| Arginine | 1 | 2014 | 349 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1999 | 1603 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 73 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2015 | 579 | 0.020 |
Why?
|
| Biomarkers | 1 | 2021 | 3424 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 813 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 607 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 386 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2836 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3168 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 4551 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 1701 | 0.020 |
Why?
|
| Proteomics | 1 | 2011 | 595 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 2651 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 1999 | 89 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 1999 | 99 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 1999 | 117 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1999 | 133 | 0.010 |
Why?
|
| Endocytosis | 1 | 1999 | 132 | 0.010 |
Why?
|
| Immunization | 1 | 1999 | 315 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1999 | 991 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1999 | 497 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 522 | 0.010 |
Why?
|